# Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

> **NCT01050842** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 18 (actual)

## Conditions studied

- Prostate Cancer
- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** bicalutamide
- **DRUG:** raloxifene
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01050842
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-05
- **Final completion:** 2012-10-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01050842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01050842, "Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01050842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*